• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Sarepta shares fall 37% as FDA questions future of key gene therapy

by July 19, 2025
by July 19, 2025

Shares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is considering whether to halt the distribution of Elevidys, the company’s flagship gene therapy for Duchenne Muscular Dystrophy (DMD).

The move comes amid an ongoing investigation into multiple patient deaths tied to Sarepta’s gene therapy programs.

A source familiar with the matter told CNBC that the FDA is preparing to request Sarepta voluntarily suspend shipments of Elevidys, though the agency has yet to formally contact the company.

Sarepta said it had not received any direct communication from the FDA as of Friday.

Separately, FDA Commissioner Marty Makary confirmed to Bloomberg News that the agency is reviewing whether Elevidys should remain on the market, raising fears that Sarepta’s primary commercial product could be withdrawn entirely.

Deaths reignite long-standing safety concerns

The FDA’s concerns follow the deaths of two teenage boys from liver failure earlier this year after receiving Elevidys.

A third patient, enrolled in a Phase 1 trial for a different Sarepta gene therapy, also died recently.

While the therapies differ in their targets, both use the same delivery mechanism, fueling broader safety concerns.

Elevidys has been controversial from the outset.

Initially granted conditional approval in 2023 for DMD patients aged 4 to 5 who could still walk, its approval was expanded in 2024 to include all ambulatory patients aged 4 and up, and conditionally for non-ambulatory patients.

The latter decision drew criticism, as clinical data showed weaker evidence of efficacy in this group.

Further concerns arose when Elevidys failed to meet its primary goal in a Phase 3 trial.

Nevertheless, former FDA official Peter Marks sided with Sarepta, citing secondary benefits in the trial to justify expanded approval, a move that has since come under renewed scrutiny.

Baird downgrades Sarepta stock; analysts warn of dire consequences if Elevidys approval revoked

The regulatory probe has dealt a blow to Sarepta, which relies heavily on Elevidys for its revenue.

The therapy accounted for more than half of Sarepta’s total net product revenue.

With the company’s shares now down more than 87% year-to-date, investors are bracing for the possibility that the FDA may revoke approval altogether.

Analyst Kostas Biliouris of BMO Capital Markets noted that while other gene therapies, such as Novartis’s Zolgensma, have also faced safety issues, the clear benefit of Zolgensma justifies the risk.

“That’s why deaths here matter so much versus Zolgensma, for example,” Biliouris said.

The company has stopped shipping Elevidys to non-ambulatory patients while it assesses alternative delivery methods.

Still, Sarepta executives insist the drug could bring in $500 million annually even if limited to treating ambulatory patients.

The company’s future now hinges on the FDA’s decision. “If the FDA pulls Elevidys from the market,” Biliouris warned, “Sarepta is done.”

“Although the development of SRP-9004 has been discontinued, we believe the death could lead to greater scrutiny of SRP-9003’s safety profile ahead of its BLA submission and could affect commercial interest, if approved,” brokerage William Blair said.

Baird downgraded Sarepta Therapeutics to Neutral from Outperform, with a $15 Price Target.

The post Sarepta shares fall 37% as FDA questions future of key gene therapy appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Talen Energy surges 25% to ATH after strategic natural gas power plant acquisition
next post
Donald Trump demands 15-20% tariffs on EU: report

Related Posts

Europe bulletin: Zelensky calls for more weapons, Russia...

October 25, 2025

Nvidia stock edges higher amid semiconductor sector rally...

October 25, 2025

AMD stock climbs 7%, breaching $400B market cap...

October 25, 2025

US digest: Jeffries endorses Mamdani, Ford’s stock surge,...

October 25, 2025

Trump seeks Asia mineral deals to ramp up...

October 25, 2025

Lucy Powell elected deputy leader of the UK’s...

October 25, 2025

Disney warns YouTube TV subscribers of potential blackout...

October 24, 2025

Top catalysts for the CAC 40 index next...

October 24, 2025

European stocks open higher, buoyed by a wave...

October 24, 2025

NatWest share price forecast as its earnings jump:...

October 24, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Europe bulletin: Zelensky calls for more weapons, Russia warns against EU sanctions

    October 25, 2025
  • Nvidia stock edges higher amid semiconductor sector rally and AI boom

    October 25, 2025
  • AMD stock climbs 7%, breaching $400B market cap amid chip sector rally

    October 25, 2025
  • US digest: Jeffries endorses Mamdani, Ford’s stock surge, US sanctions Colombian president

    October 25, 2025
  • Trump seeks Asia mineral deals to ramp up pressure on China’s Xi: report

    October 25, 2025
  • Lucy Powell elected deputy leader of the UK’s Labour Party

    October 25, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Pop Mart reports 188% profit surge, plans aggressive global expansion

    March 26, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 5

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 6

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 7

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025

Categories

  • Economy (3,000)
  • Editor's Pick (295)
  • Investing (185)
  • Stock (2,048)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Asian markets open: most futures lower; Sensex...

June 6, 2025

Reliance’s $10B clean energy push: doubling down...

July 21, 2025

Should you buy Rolls-Royce stock as it...

July 16, 2025